Vivani subsidiary Cortigent to merge into ClearOne in stock deal; Novo Nordisk to evaluate semaglutide implant

Vivani Medical, Inc.

Cortigent (Vivani subsidiary) to merge into ClearOne (Nasdaq: CLRO) for 12.5M ClearOne shares; Vivani will control combined board.
ClearOne to raise $10M-$15M via unit offering as condition to close; closing expected by Dec 28, 2026.
Vivani enters non-exclusive agreement with Novo Nordisk to evaluate NPM-139 semaglutide implant for chronic weight management.
Phase 1 first-in-human study of NPM-139 expected mid-2026 with Wegovy as active comparator.
Lock-up: 50% of Vivani's ClearOne shares locked 1 year, 50% locked 2 years.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.